Bolt Biotherapeutics Inc
BOLT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.95M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $10.95 Million |
|---|---|
| Enterprise Value | $20.54 Million |
| Earnings per Share | $-17.85 |
| Beta | 1.01 |
| Outstanding Shares | 1,690,529 |
Return
| Return on Equity | -227.37% |
|---|---|
| Return on Assets | -71.23% |
| Return on Invested Capital | -90.99% |
Valuation & Multiples
| P/E Ratio | -0.41 |
|---|---|
| PEG | 4.19 |
| Price to Sales | 3.24 |
| Price to Book Ratio | 0.93 |
| Enterprise Value to Revenue | 4.37 |
| Enterprise Value to EBIT | -0.7 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.09 |
| Debt to Equity | 1.78 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-3.39
Consensus analyst estimateRevenue Estimate
$500,000
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-3.52
Consensus analyst estimateRevenue Estimate
$426,250
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 35.30%▲ 2.51% |
|---|---|
| Total Invested | $2.31M▼ 7.12% |
| Investors Holding | 240% |
About Bolt Biotherapeutics Inc
65 employees
Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjug...